ERBB2 and neoplasm: Of mice previously treated with MVA-BN-HER2 and immune checkpoint inhibition, although 53% (9/17) showed evidence of a palpable tumor upon re-challenge within the first 10–15 days post challenge, 100% (17/17) of the mice ultimately rejected the tumors within three weeks.